PURPOSE: The increase in methicillin-resistant Staphylococcus aureus (MRSA) infections is currently a major health care problem. Vancomycin is still often the first-line anti-microbiological agent for treating such infections; however, a recent decline in efficacy of vancomycin in MRSA infections has raised concerns and accelerated the search for new antibiotics. The aim of this study was to establish a MRSA peri-implant osteomyelitis animal model for future testing of new anti-microbiological agents under typical MRSA infection conditions. METHODS: Eighteen randomised NZW-rabbits underwent a standardised surgical procedure with the insertion of a femoral bone implant. Animals were then divided into group 1 (MRSA inoculation, no antibiotics; M/N), group 2 (MRSA inoculation, Vancomyin; M/V), and group 3 (no MRSA inoculation, no antibiotics; N/N). The primary study outcome parameters were animal leucocyte count, animal weight, and animal body temperature at one, seven, and 42 days after surgery. Additionally, a histo-morphometrical score was established and adjusted to a modified histological Smeltzer score. RESULTS: Macroscopic and histo-morphometrical findings showed a peri-implant osteomyelitis in group 1 with both increased acute and chronic infection parameters in M/N, as compared to M/V and N/N, indicating that vancomycin treatment prevented typical morphological changes of MRSA peri-implant osteomyelitis. Similarly, there was a reduction in animal weight and increase in leucocyte count and body temperature in group 1 (each p < 0.005). Vancomycin treatment again resulted in significantly reduced leucocyte count and body temperature, and increased animal body weight. CONCLUSIONS: Here we have established a peri-implant MRSA osteomyelitis model that successfully combined clinical and laboratory outcome parameters of infection with histo-morphometrical results; this model appears to be valuable for future experimental use and therapeutic monitoring of new anti-microbiological MRSA drugs.
PURPOSE: The increase in methicillin-resistant Staphylococcus aureus (MRSA) infections is currently a major health care problem. Vancomycin is still often the first-line anti-microbiological agent for treating such infections; however, a recent decline in efficacy of vancomycin in MRSA infections has raised concerns and accelerated the search for new antibiotics. The aim of this study was to establish a MRSA peri-implant osteomyelitis animal model for future testing of new anti-microbiological agents under typical MRSA infection conditions. METHODS: Eighteen randomised NZW-rabbits underwent a standardised surgical procedure with the insertion of a femoral bone implant. Animals were then divided into group 1 (MRSA inoculation, no antibiotics; M/N), group 2 (MRSA inoculation, Vancomyin; M/V), and group 3 (no MRSA inoculation, no antibiotics; N/N). The primary study outcome parameters were animal leucocyte count, animal weight, and animal body temperature at one, seven, and 42 days after surgery. Additionally, a histo-morphometrical score was established and adjusted to a modified histological Smeltzer score. RESULTS: Macroscopic and histo-morphometrical findings showed a peri-implant osteomyelitis in group 1 with both increased acute and chronic infection parameters in M/N, as compared to M/V and N/N, indicating that vancomycin treatment prevented typical morphological changes of MRSA peri-implant osteomyelitis. Similarly, there was a reduction in animal weight and increase in leucocyte count and body temperature in group 1 (each p < 0.005). Vancomycin treatment again resulted in significantly reduced leucocyte count and body temperature, and increased animal body weight. CONCLUSIONS: Here we have established a peri-implant MRSA osteomyelitis model that successfully combined clinical and laboratory outcome parameters of infection with histo-morphometrical results; this model appears to be valuable for future experimental use and therapeutic monitoring of new anti-microbiological MRSA drugs.
Authors: Matthew R Craig; Kornelis A Poelstra; J Christopher Sherrell; Michael S Kwon; Etienne L Belzile; Thomas E Brown Journal: J Orthop Res Date: 2005-09 Impact factor: 3.494
Authors: Matthias D Wimmer; Thomas M Randau; Sabine Petersdorf; Geert I Pagenstert; Markus Weißkopf; Dieter C Wirtz; Sascha Gravius Journal: Int Orthop Date: 2013-07-13 Impact factor: 3.075
Authors: Hans-Georg Simank; Marco Stuber; Ronny Frahm; Lars Helbig; Harry van Lenthe; Ralph Müller Journal: Biomaterials Date: 2006-04-03 Impact factor: 12.479
Authors: M S Smeltzer; J R Thomas; S G Hickmon; R A Skinner; C L Nelson; D Griffith; T R Parr; R P Evans Journal: J Orthop Res Date: 1997-05 Impact factor: 3.494
Authors: A Saleh Mghir; A C Crémieux; R Bleton; F Ismael; M Manteau; S Dautrey; L Massias; L Garry; N Sales; B Mazière; C Carbon Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191
Authors: Christian Fölsch; Maike Federmann; Klaus D Kuehn; Clemens Kittinger; Stefan Kogler; Gernot Zarfel; Martina Kerwat; Steve Braun; Susanne Fuchs-Winkelmann; Jürgen R J Paletta; Philip P Roessler Journal: Int Orthop Date: 2014-11-08 Impact factor: 3.075
Authors: Irene I López-Torres; Pablo Sanz-Ruíz; Victor E León-Román; Federico Navarro-García; Rodrigo Priego-Sánchez; Javier Vaquero-Martín Journal: Eur J Orthop Surg Traumatol Date: 2019-03-12
Authors: Johannes Maximilian Wagner; Hannah Zöllner; Christoph Wallner; Britta Ismer; Jessica Schira; Stephanie Abraham; Kamran Harati; Marcus Lehnhardt; Björn Behr Journal: PLoS One Date: 2016-02-12 Impact factor: 3.240
Authors: Blanca Ibarra; Joaquin García-García; Galo Azuara; Blanca Vázquez-Lasa; Miguel A Ortega; Ángel Asúnsolo; Julio San Román; Julia Buján; Natalio García-Honduvilla; Basilio De la Torre Journal: J Biomed Mater Res B Appl Biomater Date: 2019-02-19 Impact factor: 3.368